/FBRX
FBRX Stock - Forte Biosciences, Inc.
Healthcare|BiotechnologyNASDAQ
$29.69+3.31%
+$0.95 (+3.31%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+118.9%upside
Target: $64.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FBRX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$29.39 – $29.99
TARGET (TP)$65.00
STOP LOSS$27.31
RISK/REWARD1:14.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.25
52W High$29.71
52W Low$4.90
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-39,000 | $-9,000 | N/A | $-36,000 | $-54,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-36,602,000 | $-32,486,000 | $-13,896,000 | $-21,486,000 | $-14,225,000 |
| Net Income | $-35,478,000 | $-31,476,000 | $-13,862,000 | $-21,708,000 | $-46,487,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-12.17 | $-24.92 | $-19.96 | $-38.85 | $-157.93 |
Company Overview
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
4 Bullish0 Neutral/Bearish
Price Targets
$48
Average Target
↑ 60.3% Upside
Now
$3
Low
$48
Average
$75
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 25th 2025 | Evercore ISI | Initiation | Outperform | $65 |
| August 18th 2025 | Guggenheim | Initiation | Buy | $75 |
| January 21st 2025 | TD Cowen | Initiation | Buy | - |
| April 8th 2024 | Ladenburg Thalmann | Upgrade | Buy | $2.75 |
Earnings History & Surprises
FBRXBeat Rate
35%
Last 17 quarters
Avg Surprise
-1296.8%
EPS vs Estimate
Beats / Misses
6/11
Last 12 quarters
Latest EPS
$-0.99
Q4 2025
EPS Surprise History
Q1 24
-257.1%
$-1.00vs$-0.28
Q2 24
-2400.0%
$-4.00vs$-0.16
Q3 24
-68.8%
$-6.75vs$-4.00
Q4 24
+32.7%
$-4.54vs$-6.75
Q1 25
+46.2%
$-2.45vs$-4.55
Q2 25
-53.9%
$-1.37vs$-0.89
Q3 25
+20.7%
$-0.96vs$-1.21
Q4 25
+4.8%
$-0.99vs$-1.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 27, 2026 | $-1.42 | — | — | — |
Q4 2025 | Nov 14, 2025 | $-1.04 | $-0.99 | +4.8% | ✓ BEAT |
Q3 2025 | Aug 14, 2025 | $-1.21 | $-0.96 | +20.7% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.89 | $-1.37 | -53.9% | ✗ MISS |
Q1 2025 | Mar 24, 2025 | $-4.55 | $-2.45 | +46.2% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-6.75 | $-4.54 | +32.7% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-4.00 | $-6.75 | -68.8% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.16 | $-4.00 | -2400.0% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.28 | $-1.00 | -257.1% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-14.25 | $-6.50 | +54.4% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | — | $-10.50 | — | — |
Q2 2023 | May 15, 2023 | — | $-8.00 | — | — |
Q1 2023 | Mar 31, 2023 | $-0.16 | $-6.00 | -3650.0% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.15 | $-4.50 | -2900.0% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-0.17 | $-5.25 | -2988.2% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.17 | $-4.25 | -2400.0% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-0.07 | $-5.25 | -7400.0% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-7.25 | $-13.50 | -86.2% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-10.00 | $-10.75 | -7.5% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-9.75 | $-9.00 | +7.7% | ✓ BEAT |
Latest News
Evercore ISI Group Initiates Coverage On Forte Biosciences with Outperform Rating, Announces Price Target of $65
📈 PositiveBenzinga•Nov 25, 2025, 12:56 PM
Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target
📈 PositiveBenzinga•Nov 17, 2025, 12:50 PM
Forte Biosciences Q3 EPS $(0.99) Beats $(1.06) Estimate
📈 PositiveBenzinga•Nov 14, 2025, 02:13 PM
Forte Biosciences Highlights FB102's Efficacy in Celiac Disease at Tampere Symposium, Underscoring Histological Protection and Symptom Relief in Phase 1b Study
📈 PositiveBenzinga•Sep 15, 2025, 01:09 PM
Forte Biosciences shares are trading higher after Guggenheim initiated coverage on the stock with a Buy rating and announced a price target of $75.
📈 PositiveBenzinga•Aug 18, 2025, 03:15 PM
Guggenheim Initiates Coverage On Forte Biosciences with Buy Rating, Announces Price Target of $75
📈 PositiveBenzinga•Aug 18, 2025, 01:03 PM
Forte Biosciences Tops Q2 Loss Forecasts
📈 PositiveThe Motley Fool•Aug 14, 2025, 08:47 PM
Forte Biosciences stock falls after pricing capital raise of $75M via securities offering
📉 NegativeSeeking Alpha•Jun 25, 2025, 08:31 AM
Frequently Asked Questions about FBRX
What is FBRX's current stock price?
Forte Biosciences, Inc. (FBRX) is currently trading at $29.69 per share. The stock has moved +3.31% today.
What is the analyst price target for FBRX?
The average analyst price target for FBRX is $65.00, based on 1 analyst.
What sector is Forte Biosciences, Inc. in?
Forte Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is FBRX's market cap?
Forte Biosciences, Inc. has a market capitalization of $0.37 billion, making it a small-cap company.
Does FBRX pay dividends?
No, Forte Biosciences, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
ALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
CRBP
Corbus Pharmaceuticals Holdings, Inc.
$8.12
Mkt Cap: $0.1B
CRDF
Cardiff Oncology, Inc.
$2.57
Mkt Cap: $0.2B
ELTX
Elicio Therapeutics, Inc.
$7.94
Mkt Cap: $0.1B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
MOLN
Molecular Partners AG
$4.39
Mkt Cap: $0.2B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
Explore stocks similar to FBRX for comparison